Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631650 | 0.91 | ALDH1A1 (0.56) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL6576136 | 0.89 | CYP3A4 (0.47) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7120480 | 0.86 | KMT2A (0.47) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7112202 | 0.86 | F10 (0.48) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7118163 | 0.84 | F10 (0.44) | F10LSS | |
| SCHEMBL5632390 | 0.82 | ALDH1A1 (0.45) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL9759900 | 0.79 | ADRB1 (0.52) | F10SMN1; SMN2AR | |
| SCHEMBL7124112 | 0.78 | F2 (0.46) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5633263 | 0.78 | F10 (0.55) | F10ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL9761013 | 0.78 | F10 (0.47) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | claimed |
| EP-0880502-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | F10 8/4885ALDH1A1 753/4885MAPT 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.